Tel Aviv - Delayed Quote ILA

Teva Pharmaceutical Industries Limited (TEVA.TA)

5,485.00

0.00

(0.00%)

At close: April 29 at 5:24:51 PM GMT+3

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks 4 days ago

TEVA
Trump Tariff Sell-Off: 3 Superb Stocks That Make for No-Brainer Buys Right Now

Short-term uncertainty has led to a golden opportunity for long-term investors.

Motley Fool 11 days ago

VZ

^GSPC

TEVA
Zacks Industry Outlook Dr. Reddy's, Sandoz and Teva Pharmaceuticals

Dr. Reddy's, Sandoz and Teva Pharmaceuticals have been highlighted in this Industry Outlook article.

Zacks 16 days ago

TEVA

^GSPC
3 Generic Drug Stocks to Watch Amid Trade War Jitters & Inflation Woes

Despite the impact of dynamic shifts in the regulatory landscape for the Zacks Medical - Generic Drugs industry, new product launches should provide some respite to RDY, SDZNY and TEVA.

Zacks 17 days ago

TEVA

^GSPC
5 of the Safest Stocks Billionaire Money Managers Bought Ahead of Wall Street's Historic Volatility

Some of Wall Street's most-prominent asset managers were scooping up shares of time-tested businesses before the stock market meltdown.

Motley Fool 19 days ago

PM

^GSPC

TEVA
Teva Pharmaceutical Industries (TEVA): Among the Top Healthcare Stocks to Buy According to Billionaire David Einhorn

We recently published a list of Top 9 Healthcare Stocks to Buy According to Billionaire David Einhorn. In this article, we are going to take a look at where Teva Pharmaceutical Industries Limited (NYSE:TEVA) stands against other top healthcare stocks to buy according to Billionaire David Einhorn. Wall Street has come down crashing on President […]

Insider Monkey 20 days ago

TEVA

^GSPC

GLRE
Teva Pharmaceutical Industries (NYSE:TEVA) Pops As FDA Expands AJOVY'S Use For Pediatric Migraine Prevention

Teva Pharmaceutical Industries (NYSE:TEVA) recently received FDA acceptance of its supplemental Biologics License Application to expand AJOVY®'s use for preventing migraines in pediatric patients, an important step with potential market impact. Despite this positive development, Teva's share price recently declined 11% over the past week. This downward movement aligns with a broader market downturn of 12% amid heightened volatility and concerns regarding proposed tariffs on pharmaceuticals...

Simply Wall St. 22 days ago

TEVA

TEVJF
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory

We came across a bullish thesis on Teva Pharmaceutical Industries Limited (TEVA) on Substack by Kontra. In this article, we will summarize the bulls’ thesis on TEVA. Teva Pharmaceutical Industries Limited (TEVA)’s share was trading at $13.94 as of April 7th. TEVA’s trailing and forward P/E were 872 and 5.37 respectively according to Yahoo Finance. After years […]

Insider Monkey 24 days ago

TEVA
Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States

EPYSQLI® (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positiveEPYSQLI will be available at a 30% discount of the Wholesale Acquisition Cost (WAC) of the reference product, Soliris® (eculizumab), making it one of the greatest cost-saving biosimilars to Soliris® in the U.S.Teva and Samsun

GlobeNewswire 25 days ago

TEVA

TEVJF
Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention

If approved for an expanded pediatric indication, AJOVY would be the first calcitonin gene-related peptide (CGRP) antagonist for migraine prevention in adults and episodic migraine prevention in pediatric patients, addressing the high unmet need for effective treatmentsAJOVY is currently the only anti-CGRP treatment for migraine prevention in adults in the U.S. that is available in both quarterly and monthly dosing options1These efforts underscore Teva’s dedication to expanding access to innovat

GlobeNewswire 25 days ago

TEVA

TEVJF
Teva announces presentation of survey study on TEV-‘749

Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announced the presentation of a patient and healthcare professional (HCP) attitudes and experiences survey study, complementing the successful Phase 3 Subcutaneous Olanzapine Extended-Release Injection Study evaluating TEV-‘749. More than 92% of patients, 87% of nurses and 72% of physicians were either satisfied or very satisfied when asked about TEV-‘749, overall, including initiation regimen, monthly dosing schedu

TipRanks 30 days ago

TEVA

TEVJF
Is Teva Pharmaceutical Industries (TEVA) the Most Undervalued Healthcare Stock to Buy According to Analysts?

We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where Teva Pharmaceutical Industries Limited (NYSE:TEVA)stands against other most undervalued healthcare stocks to buy according to analysts. Rising Healthcare Costs and the Impact of Tariffs on US-China Trade […]

Insider Monkey last month

TEVA
New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable

More than 92% of schizophrenia patients taking TEV-'749 in the SOLARIS survey were satisfied or very satisfied with the initiation regimen, dosing schedule and trial medication1New data from UZEDY® (risperidone) evaluated predictors of response in schizophrenia with efficacy observed across patient demographic and clinical characteristics in the Phase 3 RISE trialTeva continues its commitment to generating clinical insights that help advance and support optimal treatment for individuals living w

GlobeNewswire last month

TEVA

TEVJF
These Are My 3 Worst-Performing Stocks So Far in 2025 -- and the One I'm Buying More of Now

This is an expected part of investing, especially when it comes to growth stocks. Teva Pharmaceutical (NYSE: TEVA) is my worst-performing stock so far in 2025, down 27% in less than three months as of this writing. In fact, the company slightly beat expectations for both revenue and earnings.

Motley Fool last month

TEVA
Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025

TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2025 financial results on Wednesday, May 7, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast o

GlobeNewswire last month

TEVA

TEVJF
Teva Releases Q1 2025 Aide Memoire

TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2025 Aide Memoire is available on the “Investors” page on its website. Q1 2025 Aide Memoire Teva has prepared this document to assist in the financial modeling of its quarterly results. The document is based on Teva’s prior results, management’s previous commentary about Teva’s business outlook and data from select independent sources. Going forward, it is Te

GlobeNewswire last month

TEVA

TEVJF
Billionaire Stanley Druckenmiller Jettisoned Shares of Palantir and Nvidia, and Is Piling Into 3 High-Profile Turnaround Stocks

Duquesne Family Office's chief is dumping shares of Wall Street's hottest artificial intelligence (AI) stocks in favor of a trio of companies that are righting their respective ships.

Motley Fool last month

NVDA

PLTR

TEVA
Was Jim Cramer Right About Teva Pharmaceutical Industries (TEVA)?

We recently published a list of Was Jim Cramer Right About These 23 Stocks?. In this article, we are going to take a look at where Teva Pharmaceutical Industries Limited (NYSE:TEVA) stands against other stocks that Jim Cramer discussed 12 months ago. During the latest episode of Mad Money, Jim Cramer advised his viewers to […]

Insider Monkey last month

TEVA
Teva Pharmaceutical Stock Scores RS Rating Upgrade

Teva Pharmaceutical ADR shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investor's Business Daily last month

COLL

ANIP

HLN
Teva Pharmaceutical Industries (NYSE:TEVA) Sees 14% Stock Price Rise With FDA Acceptance Of New Drug Application

Teva Pharmaceutical Industries (NYSE:TEVA) saw its stock price move up 14% over the last week, a notable jump attributed partially to recent regulatory milestones. The U.S. FDA's acceptance of a Supplemental New Drug Application for UZEDY, an extended-release injectable for maintenance treatment of bipolar I disorder, highlights Teva’s ongoing efforts in drug development. Additionally, the company's pursuit of biosimilars like AVT06, targeting eye disorders, underscores its strategic focus on...

Simply Wall St. last month

TEVA

TEVJF

Performance Overview

Return	TEVA.TA	TA-125 (^TA125.TA)
YTD	-32.29%	+5.37%
1-Year	+11.19%	+31.25%
3-Year	+84.00%	+21.24%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Teva Pharmaceutical Industries Limited (TEVA.TA)

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Trump Tariff Sell-Off: 3 Superb Stocks That Make for No-Brainer Buys Right Now

Zacks Industry Outlook Dr. Reddy's, Sandoz and Teva Pharmaceuticals

3 Generic Drug Stocks to Watch Amid Trade War Jitters & Inflation Woes

5 of the Safest Stocks Billionaire Money Managers Bought Ahead of Wall Street's Historic Volatility

Teva Pharmaceutical Industries (TEVA): Among the Top Healthcare Stocks to Buy According to Billionaire David Einhorn

Teva Pharmaceutical Industries (NYSE:TEVA) Pops As FDA Expands AJOVY'S Use For Pediatric Migraine Prevention

Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory

Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States

Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention

Teva announces presentation of survey study on TEV-‘749

Is Teva Pharmaceutical Industries (TEVA) the Most Undervalued Healthcare Stock to Buy According to Analysts?

New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable

These Are My 3 Worst-Performing Stocks So Far in 2025 -- and the One I'm Buying More of Now

Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025

Teva Releases Q1 2025 Aide Memoire

Billionaire Stanley Druckenmiller Jettisoned Shares of Palantir and Nvidia, and Is Piling Into 3 High-Profile Turnaround Stocks

Was Jim Cramer Right About Teva Pharmaceutical Industries (TEVA)?

Teva Pharmaceutical Stock Scores RS Rating Upgrade

Teva Pharmaceutical Industries (NYSE:TEVA) Sees 14% Stock Price Rise With FDA Acceptance Of New Drug Application

Performance Overview